Hansen Gwenn 4

What Happened Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), had RSUs convert to common stock on Jan 30, 2026 (11,816 shares in total). Of those, she sold 4,797 shares at a weighted average of $16.58 (proceeds $79,547) and 98 shares at a weighted average of $17.37 (proceeds $1,702), for combined cash proceeds of about $81,249. The filing shows the remaining converted shares were withheld/surrendered in connection with tax withholding obligations rather than discretionary sales.

Key Details

• Transaction date: 2026-01-30 (filed same day).
• Conversion (derivative exercise/RSU settlement): 11,816 shares acquired via conversion of RSUs (exercise/conversion code M).
• Open-market sales: 4,895 shares sold (4,797 @ $16.58; 98 @ $17.37); total proceeds ≈ $81,249. Price ranges reported: $16.33–$17.32 and $17.33–$17.49 (weighted averages provided).
• Withholding/surrender: Remaining converted shares were surrendered/withheld to satisfy tax withholding (not discretionary sales) per filing footnote.
• Shares owned after transaction: Not reported in the provided summary of the filing.
• Filing timeliness: Reported and filed on 2026-01-30 (appears timely).
• Relevant footnotes: F1 = sales were mandated “sell-to-cover” for tax withholding; F4–F9 = RSU facts and vesting schedules (RSUs deliver one share upon vesting; various awards vest quarterly over multi-year schedules).

Context These transactions reflect RSU vesting and routine tax-withholding mechanics rather than a voluntary, discretionary sale for investment reasons. For retail investors, purchases or open-market buys by insiders can be a stronger signal of confidence; mandatory sell-to-cover transactions (like this one) are common when RSUs vest and generally should not be interpreted as a personal bearish view by the insider.